基于ALK的双重抑制剂:关注非小细胞肺癌治疗的近期发展
Qiu-Ge Liu1, Ji Wu2, Zi-Yue Wang2
1School of Basic Medical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
European journal of medicinal chemistry
|April 22, 2025
概括
双目标抑制剂提供了一种有前途的策略,以克服对形淋巴瘤激酶 (ALK) 阳性非小细胞肺癌 (NSCLC) 的抵抗. 这些新型疗法旨在提高治疗效率并减少对患者的毒性.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 无细胞淋巴瘤激酶 (ALK) 是非小细胞肺癌 (NSCLC) 的关键驱动因素.
- 已批准的ALK抑制剂显示有效性,但面临获得的耐药性,包括突变和绕道途径.
- 开发新的策略对于持续治疗ALK阳性NSCLC至关重要.
研究的目的:
- 审查针对NSCLC的双位ALK抑制剂的进展.
- 分析这些抑制剂的设计和结构-活性关系.
- 通过下一代疗法探索克服抗药性的前景.
主要方法:
- 在NSCLC中对双位ALK抑制剂的文献综述.
- 合理药物设计和结构-活性关系的分析.
- 讨论抵抗机制和未来的治疗方法.
主要成果:
- 双位抑制剂在缓解抵抗机制方面显示出潜在的潜力.
- 与组合疗法相比,同时针对两个途径可能会降低全身毒性.
- 最近的进展凸显了基于ALK的双重抑制剂的前景.
结论:
- 双位ALK抑制剂代表了NSCLC治疗的重大进展.
- 对合理设计和下一代抑制剂的进一步研究至关重要.
- 需要创新的治疗方法来克服耐药性并改善患者的治疗结果.
更多相关视频
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
7.8K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.7K
相关概念视频
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K
Combination Therapies and Personalized Medicine
4.8K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.8K
Drugs that Stabilize Microtubules
1.9K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
1.9K
Cancer Therapies
7.4K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.4K
